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INTRODUCTION
Transarterial chemoembolization (TACE) is widely used as 
the standard of care for the local treatment of Barcelona Clinic 
Liver Cancer stage B hepatocellular carcinoma (BCLC-B HCC). 
However, tumor cells at the periphery of HCC may remain vi-
able, as they are supplied by both arterial and portal blood. 
Complete tumor necrosis may not be induced in large HCCs.1 
Ischemic injury by TACE stimulates vascular endothelial growth 
factor production by residual tumor cells, which may induce 
neoangiogenesis and potentially cause disease recurrence.2 
Radiotherapy (RT) has been investigated as a component of 
combined treatment to compensate for the limitations of TACE. 
Several studies, including meta-analyses and prospective tri-
als, have reported significant therapeutic benefits of combina-
tion treatment using RT and TACE.3-8
In real-world practice, RT is frequently administered after 
incomplete TACE.9 However, the optimal therapeutic strate-
gies to maximize treatment outcomes have not been well de-
fined. In the clinical scenario, determination of the optimal 
timing for initiating RT is particularly important. Early admin-
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istration of RT may enhance tumor control by eradicating re-
sidual tumor cells early. However, its application is limited 
since diffuse lipiodol retention around the tumor immediately 
after TACE may obscure the tumor margin, thereby hindering 
delineation of the RT target volume.10 Furthermore, the post-
TACE acute inflammatory status of the liver with elevated liver 
function parameters may prevent the early initiation of RT.11 
Consequently, RT is usually delayed for at least a few weeks. 
Therefore, it is of particular clinical importance to identify the 
optimal timing of RT initiation after TACE.
Therefore, in a homogeneous cohort of patients with BCLC-
B HCC treated with TACE and RT, we investigated the optimal 
timing of RT initiation after incomplete TACE to determine 




We retrospectively identified patients with BCLC-B HCC who 
underwent RT after TACE at our center between July 2001 and 
September 2016. The inclusion criteria were as follows: 1) a 
diagnosis of BCLC-B HCC, 2) RT administration after TACE, 
and 3) a <6-month interval between TACE and initiation of RT. 
The exclusion criteria were as follows: 1) Child-Pugh class C, 
2) Eastern Cooperative Oncology Group performance status 
score ≥3, 3) presence of distant metastases, 4) history of other 
malignancies, 5) history of RT administration to the abdominal 
area, and 6) incomplete RT [biologically effective dose (BED) 
<40 Gy with α/β=10] due to patient refusal or poor general con-
dition. A total of 116 lesions in 104 patients were included in 
the analysis. 
Ethical statement
This study was conducted in accordance with the tenets of the 
Declaration of Helsinki. This retrospective study was approved 
by the Institutional Review Board (4-2019-0633). The require-
ment for informed consent was waived by the Institutional 
Review Board.
Treatment
TACE was performed using the conventional method. A com-
bination of 5 mL of iodized oil contrast medium (Lipiodol; Guer-
bet, Aulnay-sous-Bois, France) and 30–50 mg of doxorubicin 
(Adriamycin; Ildong Pharmaceutical, Seoul, Korea) was infused 
selectively into a subsegmental branch of the feeding artery. If 
this was impossible, a segmental branch was chosen instead. 
Embolization was subsequently performed using gelatin sponge 
particles (Cutanplast; Mascia Brunelli S.p.A., Milan, Italy). 
Identifying TACE incompleteness and necessity of additional 
RT was determined individually in the multidisciplinary dis-
cussion that included intervention radiologists, radiation on-
cologists, and hepatologists. Patients were considered for ad-
ditional RT after TACE for the following cases; progressive 
disease according to the modified RECIST criteria,12 or incom-
plete uptake of iodized oil on contrast-enhanced computed 
tomography. When the result of TACE was expected to be in-
complete due to large size of the tumor and/or poor vascular-
ity, the combination treatment of TACE and RT was planned 
from the beginning. The necessity of additional RT was deter-
mined through multidisciplinary discussion while consider-
ing the tumor and patient’s condition. Repeated TACE was 
avoided in patients compatible to TACE refractoriness13 or when 
further TACE seemed technically inaccessible.
The gross tumor volume included enhanced tumor areas, 
complete tumor areas filled by the lipiodol-doxorubicin or lipi-
odol-cisplatin mixture, and tumor areas showing complete 
tissue necrosis after TACE on dynamic enhanced computed to-
mography or magnetic resonance imaging. The clinical target 
volume included the gross tumor volume with a 5-mm margin, 
and the planning target volume was defined as the clinical tar-
get volume with a 5-mm margin. All patients were educated on 
respiratory control, and an abdominal compressor was used to 
restrict diaphragmatic movement. Before 2010, tumor move-
ment was accounted for in the planning target volume by add-
ing a margin of 1–2 cm in the craniocaudal direction. However, 
since 2010, four-dimensional computed tomography-based 
planning has been adopted. The internal target volume was de-
lineated based on the tumor movement during individual re-
spiratory phases, and 5-mm margins around the internal and 
clinical target volumes were defined as the clinical and plan-
ning target volumes, respectively.
RT doses were decided according to the physicians’ discre-
tion to maximize the dose delivered to tumor while satisfying 
the dose constraints for normal organs, such as remnant liver 
and gastrointestinal tract. Various dose fractionation sched-
ules were used: 100–60 Gy/20–30 fractions in daily >3 Gy dose, 
54–36 Gy/20–30 fractions in daily <3 Gy dose. Three-dimen-
sional conformal RT and intensity-modulated RT was used in 
89 (85.6%) and 15 (14.4%) patients, respectively. 
Statistical analysis
The time interval between the last session of TACE and RT ini-
tiation was evaluated. The optimal cut-off time interval that 
maximized the difference in the local failure-free rate (LFFR) 
was determined using maximally selected rank statistics.14 The 
LFFR, outfield intrahepatic failure-free rate, distant metastasis-
free rate, and overall survival (OS) were defined as the time be-
tween the date of RT initiation and the first event, and were an-
alyzed using the Kaplan-Meier method and log-rank test. A Cox 
regression model was used for univariate and multivariate anal-
yses of LFFR by backward stepwise model selection. Baseline 
characteristics were compared between the two groups using 
the chi-square test, Fisher’s exact test, or Student’s t-test, as ap-
propriate. The relationship between the time interval and prob-
411
Hwa Kyung Byun, et al.
https://doi.org/10.3349/ymj.2021.62.5.409
ability of 1-year local control was analyzed using logistic re-
gression. Propensity score matching between the early and 
late RT groups was performed by using a 1:1 nearest neighbor 
(greedy-type) matching and a caliper width of a 0.2 standard 
deviation of the logit distance measure. Statistical significance 
was set at a two-sided p-value of <0.05. All statistical analyses 
were performed using R software (version 3.4.1; R Foundation 
for Statistical Computing, Vienna, Austria) and SPSS software 
(version 23.0; IBM Corp., Armonk, NY, USA) packages.
RESULTS
Patient and tumor characteristics
Table 1 shows the baseline characteristics before RT. All pa-
tients had BCLC-B HCC. The median age was 59 years (range: 
34–83 years), and median tumor size was 7 cm (range: 2–20 cm). 
Of the patients, 61 (58.7%) and 43 (41.3%) had single and multi-
ple tumors, respectively. Most patients (n=96, 92.3%) had Child-
Pugh class A disease. The median number of TACE treatments 
before and after RT were 2 (range: 1–7) and 0 (range: 0–7), re-
spectively. The median time interval between TACE and RT 
initiation was 26 days (range: 2–165 days). Among the 104 pa-
tients analyzed, the median follow-up duration was 18 months 
(range: 3–160 months), and the median OS was 18.0 months. 
Optimal cut-off time interval
Among the 116 lesions, the probability of 1-year local control 
decreased with an increase in the time interval between TACE 
and RT initiation (Fig. 1). One-year LFFRs were analyzed in 
the early and late RT groups using various cut-off values (Fig. 2): 
within 2 weeks, the 1-year LFFRs were 92.6% and 80.4%, re-
spectively (p=0.299); within 3 weeks, they were 94.4% and 77.2%, 
respectively (p=0.115); within 4 weeks, they were 95.3% and 
73.9%, respectively (p=0.009); within 5 weeks, they were 94.6% 
and 70.8%, respectively (p=0.005); within 7 weeks, they were 
88.7% and 61.1%, respectively (p=0.025); and within 10 weeks, 
they were 85.3% and 70.0%, respectively (p=0.466). 
The LFFR was consistently higher in the early RT group com-
pared to the late RT group. The largest difference in LFFR was 
observed at the cut-off duration of 5 weeks, whereas the LFFR 
in the early RT group remained higher than 90% (Fig. 2D). 
Maximally selected rank statistics also revealed 5 weeks to be 
the optimal cut-off interval that maximized the difference in 
LFFR. Therefore, we selected 5 weeks as the optimal cut-off 
time interval between TACE and RT initiation.
Analyses according to early and late RT
Overall, 65 and 39 patients were included in the early RT (≤5 
weeks) and late RT (>5 weeks) groups, respectively. The total 
Table 1. Patient Characteristics (n=104)








AFP (ng/mL) 29 (1–83000)
PIVKA-II (mAU/mL) 143 (11–4751)
No. of TACE before RT 2 (1–7)
No. of TACE after RT 0 (0–7)
RT dose (Gy)* 51.5 (34–117)
RT technique





Albumin (g/dL) 3.9 (2.7–5.1)
Total bilirubin (mg/dL) 0.7 (0.2–2.6)
Prothrombin time (INR) 1.04 (0.8–1.69)
AST (IU/L) 37 (15–196)
ALT (IU/L) 26 (7–331)
ALP (IU/L) 105 (46–431)
Time interval (days) 26 (2–165)
AFP, alpha-fetoprotein; PIVKA-II, prothrombin induced by vitamin K absence-
II; TACE, transarterial chemoembolization; RT, radiotherapy; INR, internation-
al normalized ratio; AST, aspartate aminotransferase; ALT, alanine amino-
transferase; ALP, alkaline phosphatase.
Data are presented as median (range) or n (%).
*RT dose for the tumor was calculated as the equivalent dose in 2-Gy frac-
tions with α/β=10.
Fig. 1. Local control probabilities at 1 year after radiotherapy as a function 
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numbers of lesions were 69 and 47 in the early RT and late RT 
groups, respectively. Table 2 shows the comparison of the char-
acteristics of patients in the early and late RT groups. The char-
acteristics were mostly similar, with no significant differences 
in age, sex, tumor size, number of tumors, prothrombin induced 
by vitamin K absence-II levels, number of TACE treatments 
before and after RT, RT dose, as well as levels of albumin, total 
bilirubin, aspartate aminotransferase, and alanine aminotrans-
ferase. In contrast, certain characteristics, such as tumor marker 
status and liver function, were significantly poorer in the early 
RT group. Specifically, the following parameters were signifi-
cantly higher in the early RT group than in the late RT group: 
alpha-fetoprotein (median: 70 ng/mL vs. 17 ng/mL, p=0.010), 
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>7 weeks 19 15 8 5 5 3 3
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Fig. 2. LFFRs in the early and late radiotherapy groups using a cut-off time interval of (A) 2 weeks, (B) 3 weeks, (C) 4 weeks, (D) 5 weeks,  (E) 7 weeks, and 
(F) 10 weeks. The difference in the LFFRs was the greatest using a cut-off time interval of 5 weeks. LFFR, local failure-free rate.
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and alkaline phosphatase (median: 118 IU/L vs. 97 IU/L, p= 
0.037). Likewise, 8 (12.3%) patients in the early RT group had 
Child-Pugh class B disease, compared to 0 (0%) patient in the 
late RT group. 
RT initiation was individualized at referral. The reasons for 
RT delay were as follows: decreased general performance of 
patients following TACE (n=1), fever (n=1), perihepatic abscess 
(n=1), late detection of recurrent disease (n=3), low compliance 
(n=2), and high volume center-related process delays, includ-
ing delays in post-TACE imaging and patient referral (n=31). 
On univariate analysis, a time interval of >5 weeks was the 
only significant predictor of a poor LFFR. On multivariate anal-
ysis, a time interval of >5 weeks was an independent predictor 
of a poor LFFR (hazard ratio: 3.30, 95% confidence interval: 
1.50–7.29, p=0.003) (Table 3). 
Although the local failure rate was higher in the late RT 
group, the OS, outfield intrahepatic failure-free rate, and distant 
metastasis-free rate were not significantly different between 
the groups. In the early and late RT groups, the 1-year local fail-
ure rates were 5.7% and 34.6%, respectively (p=0.002); the 1-year 
outfield intrahepatic failure-free rates were 56.1% and 49.5%, 
respectively (p=0.107); the 1-year distant failure-free rates were 
67.0% and 80.6%, respectively (p=0.139); and the 1-year OS rates 
were 63.1% and 74.4%, respectively (p=0.977) (Fig. 3), when 
calculated from RT start date. When calculated from the last 
TACE date, the 1-year local failure rates were 5.7% and 31%, re-
spectively (p=0.005); and the 1-year OS rates were 63.1% and 
79.5%, respectively (p=0.680). 
After propensity score matching, the patient and tumor 
characteristics were well-balanced between the early and late 
RT groups (Supplementary Table 1, only online). The LFFR 
was significantly higher in the early RT group (p=0.004) (Fig. 4).
DISCUSSION
This study demonstrated that the likelihood of local control 






 (>5 weeks, n=39)
p value
Age (yr) 57 (37–83) 62 (34–81) 0.146
Sex 0.732
Female 10 (15.4) 7 (17.9)
Male 55 (84.6) 32 (82.1)
Largest tumor size (cm) 7 (3–20) 6 (2–20) 0.144
No. of tumors 0.090
Single 34 (52.3) 27 (69.2)
Multiple 31 (47.7) 12 (30.8)
AFP (ng/mL) 70 (1–83000) 17 (1–10172) 0.010
PIVKA-II (mAU/mL) 168 (14–2000) 91 (11–4751) 0.917
No. of TACE before RT 2 (1–7) 2 (1–5) 0.242
No. of TACE after RT 0 (0–3) 0 (0–7) 0.466




58 (89.2) 31 (79.5) 0.171
Intensity-modulated 7 (10.8) 8 (20.5)
Child-Pugh class 0.024
A 57 (87.7) 39 (100)
B 8 (12.3) 0 (0)
Albumin (g/dL) 3.9 (2.7–5.1) 3.9 (3–4.8) 0.457
Total bilirubin (mg/dL) 0.7 (0.2–2.6) 0.7 (0.2–2.1) 0.531
Prothrombin time (INR) 1.07 (0.8–1.69) 1 (0.88–1.21) 0.005
AST (IU/L) 39 (15–196) 32 (17–159) 0.530
ALT (IU/L) 30 (8–331) 24 (7–317) 0.910
ALP (IU/L) 118 (53–431) 97 (46–258) 0.037
Time interval (days) 14 (2–35) 48 (36–165) <0.001
AFP, alpha-fetoprotein; PIVKA-II, prothrombin induced by vitamin K absence-
II; TACE, transarterial chemoembolization; RT, radiotherapy; INR, internation-
al normalized ratio; AST, aspartate aminotransferase; ALT, alanine amino-
transferase; ALP, alkaline phosphatase.
Data are presented as median (range) or n (%).
*RT dose for the tumor was calculated as the equivalent dose in 2-Gy frac-
tions with α/β=10.
Table 3. Univariate and Multivariate Analyses of Factors Influencing the Local Failure-Free Rate
 
 
Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
Age, yr (continuous) 1.03 (0.99–1.06) 0.149
Sex (male vs. female) 1.37 (0.41–4.52) 0.611
Largest tumor size, cm (continuous) 1.05 (0.97–1.14) 0.244 1.07 (0.99–1.16) 0.077
No. of tumors (multiple vs. single) 0.67 (0.31–1.45) 0.304
AFP, ng/mL (continuous) 1.00 (1.00–1.00) 0.662
PIVKA-II, mAU/mL (continuous) 1.00 (1.00–1.00) 0.195
No. of TACE before RT (continuous) 0.91 (0.65–1.27) 0.568
No. of TACE after RT (continuous) 1.12 (0.83–1.52) 0.467
RT dose, Gy (continuous)* 0.98 (0.93–1.03) 0.483
Time interval (>5 weeks vs. ≤5 weeks) 2.92 (1.34–6.35) 0.007 3.30 (1.50–7.29) 0.003
AFP, alpha-fetoprotein; PIVKA-II, prothrombin induced by vitamin K absence-II; TACE, transarterial chemoembolization; RT, radiotherapy; HR, hazard ratio; CI, con-
fidence interal.
*RT dose for the tumor was calculated as the equivalent dose in 2-Gy fractions with α/β=10.
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increases with a decrease in the time interval between TACE 
and RT. Based on the estimated optimal cut-off time interval of 
5 weeks, patients were categorized into the early and late RT 
groups; patient characteristics were mostly similar between 
the groups. However, certain characteristics, including tumor 
marker status and liver function, were poorer in the early RT 
group than in the late RT group. Nevertheless, the early RT 
group had a higher LFFR than the late RT group (1-year LFFR: 
94.6% vs. 70.8%; p=0.005). Moreover, early administration of 
RT was an independent predictor of a favorable LFFR.
Considering the increasing clinical evidence in favor of 
TACE with RT, the addition of RT after incomplete TACE has 
become increasingly popular in clinical practice.3-7 However, 
the optimal radiation dose/fractionations, radiation tech-
niques, strategies of combining TACE with RT (RT before TACE, 
RT sandwiched between TACE treatments, or RT following 
TACE), and time interval between TACE and RT remain un-
clear. We previously investigated the optimal RT dose for TACE 
with RT treatments and concluded that a higher BED (≥72 Gy) 
improved local control and progression-free survival.15 In line 
with the previous study, we evaluated the optimal timing of RT 
after incomplete TACE that may maximize treatment benefits. 
So far, the time interval between TACE and RT varies across 
literature. Our previous prospective phase II trial that investi-
gated the efficacy and toxicity of TACE with RT adopted a time 
interval between 4 and 6 weeks.5 A randomized clinical trial 
comparing TACE with RT and sorafenib used a time interval 
of <3 weeks.3 Likewise, most studies have used time intervals 
between 2 and 8 weeks.6 However, no study has yet investigated 
the effect of the time interval between TACE and RT on treat-
ment outcomes. Among our patients, the time interval varied 
between 2 days and 5 months, and we evaluated the effect of 
the time interval on treatment outcomes.
In this study, the improvement in LFFR owing to early RT 
may be attributed to several factors. First, in patients receiving 
early RT, the higher retention of chemotherapeutic agents in 
liver tumor cells after embolization may enhance the radio-
sensitizing effect. Second, early RT may eradicate residual tu-
mor cells after TACE before regrowth of the residual tumor. 
Third, early initiation may allow the administration of RT be-
fore ischemic injury from TACE induces a neoangiogenic re-
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Fig. 3. (A) Local failure-free rate (LFFR), (B) outfield intrahepatic failure-free rate, (C) distant failure-free rate, and (D) overall survival (OS) rate in patients 
with cut-off time intervals of ≤5 weeks and >5 weeks.
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demonstrated that the levels of two angiogenic factors, namely, 
vascular endothelial growth factor and basic fibroblast growth 
factor, increase after TACE.16 Improved tumor control may be 
anticipated in patients in whom RT is administered before tu-
mor neoangiogenesis. However, although insignificant, the 
distant-failure free rate was slightly lower in the early RT group 
than in the late RT group. This may be due to the more advanced 
cancer in the early RT group, as can be seen by higher AFP level.17 
Early administration of RT only affected local control; howev-
er, since RT is a local therapy, it did not affect distant metasta-
sis or outfield intrahepatic failure. 
Certain clinical situations may hinder the early initiation of 
RT after TACE. Diffuse peritumoral retention of lipiodol is com-
monly observed on simulation computed tomography imme-
diately after TACE.10 This obscures the precise tumor margin 
and hinders radiation oncologists from defining accurate RT 
target volumes. Furthermore, an elevation in liver function pa-
rameters is common immediately after TACE.11 Therefore, ad-
ditional RT at this point may lead to hepatic decompensation 
and liver failure. Delays in decision making, imaging, RT plan-
ning, or referral processes may also delay the initiation of RT, 
and this was the main reason for the RT delay in this study. 
Therefore, we suggest that patients who could benefit from 
additional RT be referred and prepared for RT planning expe-
ditiously after multidisciplinary discussion. 
In our study, implementing the cut-off time interval of 2 or 3 
weeks yielded no significant differences in LFFR between the 
early and late RT groups, implying that very early addition of 
RT (within 2–3 weeks) may be unnecessary. Among our patients, 
the transiently elevated liver function parameters after TACE 
usually normalized within 2–3 weeks. Therefore, we speculate 
that very early initiation of RT is unnecessary and may increase 
hepatic toxicity. RT initiation within 3–5 weeks after TACE is 
safe and optimal. 
This study had several limitations. First, this was a retrospec-
tive study extending over a long duration; treatment policies 
have changed over this period, particularly in terms of RT dose 
prescription. However, this homogeneous cohort included 
patients with BCLC-B HCC who were treated with TACE and RT, 
thereby allowing the evaluation of the sole effect of time inter-
vals on treatment outcomes. Second, this study revealed no 
significant relationship between the LFFR and RT dose. This 
was in contrast to the findings of our previous study, which con-
cluded that a BED ≥72 Gy was associated with better local con-
trol.15 However, the patient group in this study was different 
from that in the previous study. The previous study included 
patients with all BCLC disease stages, whereas this study se-
lectively included BCLC-B HCC patients, and only a small pro-
portion of patients (n=12, 11.5%) received radiation doses ex-
ceeding a BED of 72 Gy. Nevertheless, our findings should be 
interpreted with caution considering these limitations.
In conclusion, this study revealed that the probability of lo-
cal control may be improved by administering RT as early as 5 
weeks after TACE. A multidisciplinary discussion involving in-
terventional radiologists, radiologists, radiation oncologists, 
surgeons, and hepatologists may expedite the identification of 
cases of incomplete TACE and emphasize the necessity of ad-
ditional local treatment. This will facilitate early administration 
of RT after incomplete TACE. Future prospective studies are 
needed to validate our findings.
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